One way deterministic sensitivity analysis results
| NSAID model | Benzodiazepine model | PPI model | |
| Incremental effect (QALYs) | |||
| Outcome discount rate | |||
| 0 | −0.157 | −0.175 | −0.035 |
| 0.02 | −0.111 | −0.115 | −0.022 |
| 0.04 | −0.082 | −0.079 | −0.014 |
| 0.06 | −0.061 | −0.056 | −0.010 |
| Non-adherence to treatment | |||
| 10% | −0.064 | −0.059 | −0.011 |
| 20% | −0.058 | −0.052 | −0.010 |
| Incremental cost (€) | |||
| Costs discount rate | |||
| 0 | 1145.45 | 6497.62 | 1767.79 |
| 0.02 | 984.56 | 4978.65 | 1379.78 |
| 0.04 | 858.79 | 3893.76 | 1099.22 |
| 0.06 | 758.79 | 3108.09 | 893.40 |
| Inpatient cost of C. difficile | |||
| €4000.00 | – | – | 961.63 |
| €6398.72 | – | – | 996.79 |
| €8797.45 | – | – | 1031.94 |
| €11 196.17 | – | – | 1067.09 |
| PIP drug cost* | |||
| Low | 349.20 | 3016.20 | 478.15 |
| High | 1125.73 | 4474.65 | 2166.44 |
| Non-PIP drug cost† | |||
| Low | 1192.38 | – | 1673.52 |
| High | 660.57 | – | 477.64 |
| Non-adherence to treatment | |||
| 10% | 740.56 | 3117.12 | 900.42 |
| 20% | 672.11 | 2765.54 | 810.45 |
*PIP drug cost range (€) NSAID: 74.82–202.00, benzodiazepine: 38.96–164.16, PPI: 117.12–261.60.
†Non-PIP drug cost range (€) NSAID: 38.40–120.00, PPI: 56.56–160.80.
ICER, incremental cost-effectiveness ratio; LYs, life years; NSAID, non-steroidal anti-inflammatory drug; PPI, proton pump inhibitor; QALYs, quality-adjusted life years.